De Mossel 11a, 1723 HZ Noord-Scharwoude |
Growth Factor Release
Chemoattraction
Cell Differentiation
Bone Marrow aspirate ConCentrate
Stem Cells
Human stem cells have the capability to self-replicate or
differentiate into the cell types that make up all tissues and
organs of the human body. Under normal conditions, the
human body has sufficient stem cells to support natural
tissue maintenance and healing, but often lacks the quantity
of stem cells necessary to successfully
regenerate severely damaged tissues.
Harvest’s stem cell development
strategy seeks to overcome this
shortage of stem and regener-
ative cells by concentrating
“hidden” populations of
the patient‘s own stem
cells in a point-of-care
setting for treatments to
promote tissue repair and
regeneration. (Fig. 4)
Stem Cell Sources
there are numerous sources of human
stem cells. adult stem cells are the least contro-
versial and may be collected from the bone marrow,
blood or other tissues.
the
system utilizes only bone marrow-derived stem
cells obtained from the ileum in a minimally invasive process.
the cells are not chemically manipulated or cultured risking cell
viability or their ability to regenerate damaged tissue.
Autologous Regenerative Cells (ARC’s)
arC’s are harvested from a specific patient and returned
to the same patient in a point-of-care procedure. as patients
receive their own cells, there is no concern of rejection or
need for immunosuppressive drugs.
arC’s integrate effectively and interact with the surrounding
tissue to promote healing.
the Harvest system provides significantly higher cellular yields
and the treatment effect is greater compared to Ficoll. arC’s
are not removed from their natural plasma environment which
sustain functionality and may support paracrine mechanisms
that regulate cell homing, transmigration, and differentiation.
(Fig. 5)
ARC’s as Therapeutics
adult stem cells have a long history of human use as
therapeutics beginning with bone marrow transplantation,
and continuing with cell-based clinical trials focused on
tissue repair.
Harvest seeks to leverage the history and therapeutic potential
of bone marrow stem cells by producing a mixed population
of stem and early stage progenitor cells that are capable of
differentiating into a variety of tissues.
the key advantage of Harvest’s arC’s is that the number of
multi-potent stem, progenitor, and other regenerative cells are
significantly concentrated in the patient’s own physiological
plasma in a point-of-care procedure within 15 minutes.
Ficoll
Fig. 4
Fig. 5
250
50
Migrated Cells [%]
p<0.05 vs. Ficoll
